92
Participants
Start Date
July 18, 2019
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
LIQ861 Inhaled Treprostinil
LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Alleghany General Hospital, Pittsburgh
UPMC Presbyterian Hospital, Pittsburgh
INOVA Fairfax Medical Campus, Falls Church
Emory University School of Medicine, Atlanta
Mayo Clinic-Jacksonville, Jacksonville
University of Florida, Gainesville
AdventHealth, Orlando
University of Cincinnati Medical Center, Cincinnati
Mayo Clinic-Rochester, Rochester
Northwestern Medicine, Feinberg School of Medicine, Chicago
University of Chicago Medicine, Chicago
University of Kansas Medical Center, Kansas City
Ochsner Medical Center, New Orleans
UT Southwestern Medical Center, Dallas
Houston Methodist Lung Center, Houston
University of Texas Health Science Center at San Antonio, San Antonio
University of Colorado Anschutz Medical Campus, Aurora
Banner University Medical Center, Phoenix
Arizona Pulmonary Specialists, Ltd., Phoenix
University of New Mexico Health Science Center, Albuquerque
West Los Angeles VA Healthcare Center, Los Angeles
Los Angeles Biomedical Research Center, Torrance
UC Davis Medical Center, Sacramento
Oregon Health and Science Center, Portland
Tufts Medical Center, Boston
Lead Sponsor
Nuventra, Inc.
INDUSTRY
Liquidia Technologies, Inc.
INDUSTRY